Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOLIRIS vs ANTHIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis,Atypical hemolytic uremic syndrome (a HUS) to inhibit complement-mediated thrombotic microangiopathy,Generalized myasthenia gravis (g MG) in adult patients who are anti-acetylcholine receptor antibody-positive,Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 antibody-positive
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (a HUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Eculizumab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Metabolized by exonucleases to shorter oligonucleotides.
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Eculizumab is a recombinant humanized monoclonal antibody; it does not bind to serum proteins significantly. Protein binding is negligible (approximately 0%), as it is a large protein molecule.
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
Volume of distribution at steady state: approximately 7.5 L (0.11 L/kg in a 70 kg adult), indicating distribution primarily within the vascular and interstitial spaces, consistent with limited extravascular distribution of a large monoclonal antibody.
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
Intravenous administration only; bioavailability is 100% by the intravenous route. No oral or other routes are available.
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
No dose adjustment required based on GFR. Eculizumab is not renally cleared.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No specific guidelines for hepatic impairment; likely no adjustment needed as metabolism is not hepatic.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
For a HUS: weight-based: 5 to <10 kg: 300 mg; 10 to <20 kg: 600 mg; 20 to <30 kg: 600 mg; 30 to <40 kg: 900 mg; >=40 kg: 900 mg. Induction: weekly x4, then dose 1 week later, then maintenance every 2 weeks. For PNH: not approved in children <18 years.
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
No specific dose adjustment. Monitor for infections, especially meningococcal, as elderly may have increased susceptibility.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
SOLIRIS increases the risk of meningococcal infections. Patients must receive meningococcal vaccination at least 2 weeks prior to administration, unless the risks of delaying therapy outweigh the risks of developing a meningococcal infection. Patients should be monitored for early signs of meningococcal infection and evaluated immediately if infection is suspected.
None.
Increased susceptibility to meningococcal infections due to complement inhibition; vaccinate and monitor,Other Neisseria species and encapsulated bacteria infections (e.g., Streptococcus pneumoniae, Haemophilus influenzae type b); consider vaccination,Infusion reactions: including anaphylaxis and hypersensitivity; discontinue if severe,Monitoring for hemolysis in PNH patients: discontinue if evidence of severe hemolysis,Monitoring for thrombotic microangiopathy (TMA) in a HUS patients: discontinue if TMA complications occur
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
Unresolved serious Neisseria meningitidis infection,Patients not currently vaccinated against Neisseria meningitidis (unless delays in therapy outweigh risks),Known hypersensitivity to eculizumab or any of its excipients
Hypersensitivity to oblimersen or any component of the formulation
No clinically significant food interactions reported; administer intravenously over 35 minutes.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
First trimester: No adequate human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Both mother and fetus may have increased risk of infections due to complement inhibition; monitor for meningococcal and other infections. No known structural teratogenicity.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
No human data; eculizumab is a large monoclonal antibody likely to be present in minimal amounts in breast milk due to molecular size; M/P ratio unknown. Caution advised.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
No formal studies; pharmacokinetics may be altered due to increased plasma volume and renal function; consider monitoring drug levels if available, but no specific dose adjustment recommended.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
Administer meningococcal vaccines at least 2 weeks prior to first dose; vaccinate against Neisseria meningitidis serogroups A, C, Y, W-135 and serogroup B. Monitor for hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) after discontinuation. Do not administer live vaccines. Infusion reactions may occur; premedicate with antihistamines and corticosteroids if needed. Eculizumab increases risk of serious infections, especially encapsulated bacteria. Prescribe prophylactic antibiotics if vaccination cannot be given 2 weeks prior. Monitor LDH, hemoglobin, and reticulocyte count in PNH.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
You must receive meningococcal vaccines at least 2 weeks before starting treatment.,This medication increases your risk of serious infections, especially meningitis.,Report any signs of infection such as fever, headache with stiff neck, or rash immediately.,Do not receive live vaccines while on this medication.,If you stop treatment, your healthcare provider will monitor you for red blood cell breakdown.,Promptly report any bruises, bleeding, or signs of injection site reaction.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOLIRIS vs ANTHIM, answered by our medical review team.
SOLIRIS is a Monoclonal Antibody that works by Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.. ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOLIRIS and ANTHIM depend on the specific clinical indication. These are both Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOLIRIS is: 600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (a HUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.. The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOLIRIS and ANTHIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOLIRIS is classified as Category C. First trimester: No adequate human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Both mother and fetus may have increased risk of infections. ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.